BofA Securities resumed coverage on Pfizer with a new price target
$PFE
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities resumed coverage of Pfizer with a rating of Neutral and set a new price target of $29.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2024 | $29.00 | Neutral | BofA Securities |
| 11/15/2024 | $25.00 | Underperform | Wolfe Research |
| 10/25/2024 | $30.00 | Neutral | Citigroup |
| 10/17/2024 | $32.00 | Mkt Perform | Bernstein |
| 8/7/2024 | Neutral → Outperform | Daiwa Securities | |
| 3/22/2024 | Buy → Hold | Argus | |
| 2/23/2024 | $36.00 | Buy | Guggenheim |
| 1/4/2024 | $32.00 | Outperform → Market Perform | TD Cowen |
BofA Securities resumed coverage of Pfizer with a rating of Neutral and set a new price target of $29.00
Wolfe Research initiated coverage of Pfizer with a rating of Underperform and set a new price target of $25.00
Citigroup resumed coverage of Pfizer with a rating of Neutral and set a new price target of $30.00
SC 13G/A - PFIZER INC (0000078003) (Subject)
SC 13D - PFIZER INC (0000078003) (Filed by)
SC 13G/A - PFIZER INC (0000078003) (Subject)
Stuart Therapeutics adds recognized leaders in ophthalmology therapeutics development, commercialization. STUART, Fla., Dec. 22, 2024 /PRNewswire/ -- Stuart Therapeutics announced today the appointment of Tracy Valorie and Jason Werner to the company's Board of Directors, bringing the total number of Board members to five. These new Directors will hold the positions previously held by Robert O. Baratta, MD, who passed away suddenly in the third quarter of this year, and retired US Representative Diane Black, RN, who recently resigned her position on the company's Board. Tracy
Chris Boshoff to lead all Research and Development functions including Oncology Oncology Unit end-to-end structure to remain intact, reporting to Boshoff Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer Pfizer Inc. (NYSE:PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer wa
Pfizer Inc. (NYSE:PFE) today announced the election of Mortimer ("Tim") J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Mr. Buckley, age 55, was also appointed to and will join the Governance and Sustainability Committee and the Audit Committee of Pfizer's Board. Following the appointment of Mr. Buckley, the Board will comprise 14 directors, 13 of whom are independent. Mr. Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024. Previously he was Vanguard's Chief Investment Officer, overseeing the company's internally managed stock, bond and money market portf
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Fourth Quarter and Full Year 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also liste
Full-Year 2025 Revenue Guidance(1) Range of $61.0 to $64.0 Billion Full-Year 2025 Adjusted(2) Diluted EPS Guidance Range of $2.80 to $3.00 Expect Full-Year 2025 Adjusted(2) Diluted EPS Operational(3) Growth of 10% to 18% from the Midpoint of 2024 Guidance After Adjusting for 2024 Non-Recurring Items(4) Achieved Goal of $4.0 Billion in Net Cost Savings Through 2024 and Anticipate an Additional $500 Million in Savings in 2025 from Ongoing Cost Realignment Program First Phase of Manufacturing Optimization Program On Track to Deliver Initial Net Cost Savings in the Latter Part of 2025, Toward Goal of Improving Gross Margin Performance Pfizer Inc. (NYSE:PFE) today provided its fu
Board of Directors approves increase in quarterly cash dividend to $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will be the 345th consecutive quarterly dividend paid by Pfizer. "Our decision to increase our quarterly dividend underscores our strong financial performance, disciplined execution and our commitment to returning value to our shareholders," said Dr. Albert Bourla, Pfiz
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
Stuart Therapeutics adds recognized leaders in ophthalmology therapeutics development, commercialization. STUART, Fla., Dec. 22, 2024 /PRNewswire/ -- Stuart Therapeutics announced today the appointment of Tracy Valorie and Jason Werner to the company's Board of Directors, bringing the total number of Board members to five. These new Directors will hold the positions previously held by Robert O. Baratta, MD, who passed away suddenly in the third quarter of this year, and retired US Representative Diane Black, RN, who recently resigned her position on the company's Board. Tracy
BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients with metastatic colorectal cancer with a BRAF V600E mutation Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the Phase 3 BREAKWATER trial Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as det
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Fourth Quarter and Full Year 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also liste
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter
Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:
For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro
8-K - PFIZER INC (0000078003) (Filer)
10-Q - PFIZER INC (0000078003) (Filer)
8-K - PFIZER INC (0000078003) (Filer)